Suppression of MET Signaling Mediated by Pitavastatin and Capmatinib Inhibits Oral and Esophageal Cancer Cell GrowthCombined Pitavastatin and Capmatinib Inhibits Tumor Growth

Overview of attention for article published in Molecular Cancer Research, December 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#29 of 1,903)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 3,943 followers.

RT @tmdu_pr: 【研究成果発表】「ピタバスタチンによる抗腫瘍効果の解明」－既承認薬再配置を基盤とした新規がん治療戦略への期待－（難治疾患研究所教授稲澤譲治、助教村松智輝）プレスリリース https://t.co/Z0EAzXSGnm DOI：ht…

A new paper by Bo Xu, Tomoki Muramatsu and Johji Inazawa : Suppression of MET signaling mediated by pitavastatin and capmatinib inhibits oral and esophageal cancer cell growth @MCR_AACR https://t.co/nUWZUNJVPU DOI: https://t.co/mQrYLc4RLA #東京医科歯科大学 #tmd

【研究成果発表】「ピタバスタチンによる抗腫瘍効果の解明」－既承認薬再配置を基盤とした新規がん治療戦略への期待－（難治疾患研究所教授稲澤譲治、助教村松智輝）プレスリリース https://t.co/Z0EAzXSGnm DOI：https://t.co/Mpj21hmwO3 #東京医科歯科大学 #tmdu https://t.co/9txmnBGiJs

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.